Obermatt
See Similar Stocks →

Vanda Pharmaceuticals

NMQ:VNDA · US9216591084
BiotechnologySmall

360

58
Profit price24
Owner Earnings Yield1
Dividend Yield1
Price/Sales100
EV / Gross Profit89
Price/Book64
Return on Capital57
Cash Return on Capital36
Return on Equity43
EBIT Margin34
Gross Profitability88
Accruals89
Owner Earnings Margin45
Sales growth41
Profit growth71
Reinvestment23
Price momentum48
Debt load72
Refinancing12
Debt Payback1
Liquidity65
Analyst ratings38
Opinion Changes50
Price Target Upside69
Market mood23
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Vanda Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2002
Employees530
Websitevandapharma.com
ISINUS9216591084
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Sleep TechnologyDermatologyChronic DiseasesNeurologyHematologyPsychiatryOncologyCentral Nervous SystemBiopharmaBiotechnologyHealth Care

Description

Vanda Pharmaceuticals Inc. (Vanda), a global biopharmaceutical company, focuses on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The company strives to advance no…

Analysis

Middle-of-the-road

Vanda Pharmaceuticals Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
50
2026

All-time high

64

Mar 2026

All-time low

50

Jun 2026

Average rank

57

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
—
—
—
Price/Earnings
—
—
—
—
Price/Book
64
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
84
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Vanda Pharmaceuticals with its peers
TG Therapeutics
NAQ:TGTX
77
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Immunic
NAQ:IMUX
38
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Enanta Pharmaceuticals
NSQ:ENTA
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Zenas Biopharma
NSQ:ZBIO
42
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Crescent Biopharma
NAQ:CBIO
19
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Xenon Pharmaceuticals
NMQ:XENE
28
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →